BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11212236)

  • 1. Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.
    Lücke CD; Philpott A; Metcalfe JC; Thompson AM; Hughes-Davies L; Kemp PR; Hesketh R
    Cancer Res; 2001 Jan; 61(2):482-5. PubMed ID: 11212236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients.
    Shin KH; Park YJ; Park JG
    Clin Cancer Res; 2000 Feb; 6(2):536-40. PubMed ID: 10690536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
    Goggins M; Shekher M; Turnacioglu K; Yeo CJ; Hruban RH; Kern SE
    Cancer Res; 1998 Dec; 58(23):5329-32. PubMed ID: 9850059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic human breast cancers.
    Takenoshita S; Mogi A; Tani M; Osawa H; Sunaga H; Kakegawa H; Yanagita Y; Koida T; Kimura M; Fujita KI; Kato H; Kato R; Nagamachi Y
    Oncol Rep; 1998; 5(2):367-71. PubMed ID: 9468559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation analysis of the transforming growth factor-beta type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-beta.
    Vincent F; Nagashima M; Takenoshita S; Khan MA; Gemma A; Hagiwara K; Bennett WP
    Oncogene; 1997 Jul; 15(1):117-22. PubMed ID: 9233784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma.
    Anbazhagan R; Bornman DM; Johnston JC; Westra WH; Gabrielson E
    Cancer Res; 1999 Jul; 59(14):3363-4. PubMed ID: 10416594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
    Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM
    Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast.
    Vincent F; Hagiwara K; Ke Y; Stoner GD; Demetrick DJ; Bennett WP
    Biochem Biophys Res Commun; 1996 Jun; 223(3):561-4. PubMed ID: 8687435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line.
    Park B; Jang JS; Park K
    Int J Oncol; 2000 Sep; 17(3):473-8. PubMed ID: 10938386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
    Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
    Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
    Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
    Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
    Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
    Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells.
    Biswas S; Trobridge P; Romero-Gallo J; Billheimer D; Myeroff LL; Willson JK; Markowitz SD; Grady WM
    Genes Chromosomes Cancer; 2008 Feb; 47(2):95-106. PubMed ID: 17985359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.
    Mourskaia AA; Dong Z; Ng S; Banville M; Zwaagstra JC; O'Connor-McCourt MD; Siegel PM
    Oncogene; 2009 Feb; 28(7):1005-15. PubMed ID: 19079339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
    Tanaka S; Mori M; Mafune K; Ohno S; Sugimachi K
    Br J Cancer; 2000 May; 82(9):1557-60. PubMed ID: 10789724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
    Biswas S; Chytil A; Washington K; Romero-Gallo J; Gorska AE; Wirth PS; Gautam S; Moses HL; Grady WM
    Cancer Res; 2004 Jul; 64(14):4687-92. PubMed ID: 15256431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
    Deacu E; Mori Y; Sato F; Yin J; Olaru A; Sterian A; Xu Y; Wang S; Schulmann K; Berki A; Kan T; Abraham JM; Meltzer SJ
    Cancer Res; 2004 Nov; 64(21):7690-6. PubMed ID: 15520171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanism of resistance to growth inhibition by transforming growth factor-beta 1 (TGF-beta 1) in primary lung cancer and new molecular targets in therapy].
    Gemma A; Uematsu K; Hagiwara K; Takenoshita S; Kudoh S
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1253-9. PubMed ID: 10945024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
    Osada H; Tatematsu Y; Masuda A; Saito T; Sugiyama M; Yanagisawa K; Takahashi T
    Cancer Res; 2001 Nov; 61(22):8331-9. PubMed ID: 11719467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.